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Abstract
Emollients are acknowledged as a part of standard care in therapeutic and prevention
protocols as well as a part of everyday skin care routine. When it comes to making a
final decision between two emollient products, the ingredient list, that is, the formu-
lation composition could be the determining factor. In such cases the consumer, and
some healthcare providers, believe that products with the same qualitative composi-
tion (ingredient list) must have the same efficacy. In this study, we have investigated
the skin hydration performance of two emollient preparations (DBG and MBG),
which appear to contain the same ingredients, and hence, could be considered inter-
changeable in everyday practice. Our studies showed that the effects of DBG were
overall superior to the ones attributed to MBG at each investigated time point (1, 2,
4, and 24 h post application) when tested on normal and dry skin. Consequently, it is
shown that two apparently qualitatively identical products do not necessarily provide
matching efficacy.
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1 | INTRODUCTION
In topical products, the formulation itself and the specific microstruc-
ture, which is the result of complex interplay of formulation compounds,
is recognized as one of the products critical quality attributes.1-4 For
emollients, which lack in conventional therapeutically “active” sub-
stances, efficacy depends on the performance of the whole formulation.
The use of emollients in everyday life is extensive and their
importance is well recognized for both medical and cosmetic pur-
poses.5-7 Emollients are acknowledged as a part of certain therapeutic
protocols such as atopic dermatitis and various dry skin condi-
tions.6,8-10 Nevertheless, there are no specific requirements and/or
recommendations regarding vehicle systems and types of moisturizers
used in dermatological therapy.11,12
For the prescribed emollients, it is a physician who commonly
defines its use and their decision making is usually supported by the
best-practice statements and guidelines.13,14 On the other hand, for
an average consumer of cosmetic products, decision making is based
on a range of different attributes and marketing information. How-
ever, when it comes to making a final decision between two emollient
products, the ingredient list, that is, the formulation composition is
likely to have a major impact. In such cases not only that consumers/
patients but also clinicians/policy makers believe that the products
with the same ingredient list have the same efficacy.
In the light of emollient importance in dry skin condition treat-
ment, the majority of studies involving emollients address dry skin,
but the normal skin, which can also experience occasional episodes of
dryness, deserves the same consideration.15,16 Also, studies
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concerning efficacy of emollients are mainly focused on the efficacy
of an “active” in emollient products or on the correlation between dif-
ferent types of vehicles, but there is a lack of relevant, published data
addressing both well-established emollients and new emollient
formulations.17-21
Here, we highlight important efficacy shortcomings of the
assumption that two quantitatively the same emollient products can
be used therapeutically interchangeable by presenting the results of
our studies. It was our aim to compare the human skin moisturisation
effects of two qualitatively the same emollients within different prod-
ucts categories prescribed by UK doctors. As representative products
which satisfied this aim, Doublebase Gel (Diomed Developments
Ltd—a licensed medicine) and Myribase Gel (Penlan Healthcare—a
Class I medical device and branded generic), were investigated. To the
best of our knowledge, similar studies that may be relevant to every-
day physicians' practice have not been published.
2 | MATERIALS AND METHODS
The investigated preparations MyriBase Gel (MBG) and Doublebase
Gel (DBG) both list the following ingredients: Water, Isopropyl
Myristate, Liquid Paraffin, Glycerol, Carbomer, Sorbitan Laurate, Tri-
ethanolamine, and Phenoxyethanol. The qualitative composition was
provided on the packaging material, but information related to quality
standards of ingredients, the quantitative composition, or to the
manufacturing process, were not disclosed. However, both products
are labeled to contain 15% of each of Isopropyl Myristate and Liquid
Paraffin.
In order to investigate the emollients' efficacy, 40 volunteers
(both genders with normal, healthy skin) participated in each study.
The studies were conducted on volar aspects of both forearms
(randomization established in advance) as double-blind, randomized,
and bilateral. Two test sites (25 cm2 each) were used for the applica-
tion of investigated (MBG and DBG) products, while the third site
served as a non-treated control. The study was conducted in compli-
ance with the Declaration of Helsinki and in accordance with Good
Clinical Practice, valid guidelines and recommendations, and approved
by the local Ethics Committee (approval No. 2458/2).22
The volunteers were obliged not to use other products on the
test sites 2 days before the study as well as throughout the study.
During the study they were not permitted to bath or shower. Prior to
each measurement, the volunteers rested in acclimatized premises
(t = 22 ± 1C and RH = 35 ± 5%) for 30 min. The stratum corneum
moisturization (SCM) level measurements were performed by Cut-
ometer MPA 580 with an integrated CorneometerCM 825 (Courage &
Khazaka, Germany).
2.1 | Study 1 protocol
The levels of SCM were measured before product application to
obtain the initial/baseline values. Subsequently, 4.5 μL/cm2 of the
samples were applied by the investigator to the defined test sites. The
third test site served as the non-treated control. After sample applica-
tion, corneometry readings were conducted after 1, 2, 4, and 24 h.
The readings for each test site were expressed as the mean values of
15 measurements.
2.2 | Study 2 protocol
In order to induce dryness in otherwise healthy skin, a previously
established protocol was used in accordance with relevant guide-
lines.23 Sodium lauryl sulphate (SLS), 10% (w/w) solution in 100 μL,
was applied to test sites (25 cm2). On the top of a cotton pad
impregnated with the SLS solution, an occlusive film (Parafilm, Ger-
many) and a hypoallergenic adhesive tape (Sensifix, Serbia) were
placed. The entire SLS patch was removed after 6 h and the treated
skin was rinsed with tap water. A baseline measurement was taken
48 h after the dry skin induction. After successful dry skin induc-
tion, the study protocol was equivalent to the one described in
Study 1.
2.3 | Statistical analysis
Statistically significant changes were quantified at two levels: five dif-
ferent time points (0 [basal/initial value], 1, 2, 4, and 24 h post sample
application) for each treatment, and three different treatments (DBG
application, MBG application and non-treated control NC—no applica-
tion). In order to investigate the difference, two-way ANOVA was
performed and a post-hoc Bonferroni t-test was conducted where
appropriate, for all pairwise comparisons within the data set.
Statistical analysis was carried out using SigmaStat (Version 3.1,
Virginia) with significance levels set at P < .05.
3 | RESULTS
In Figure 1A, results obtained on normal skin (Study 1) are pres-
ented. After application of DBG, SCM values were significantly
increased after 1, 2, 4, and 24 h, when compared to baseline values
and non-treated control. Changes between SCM values at different
time points and baseline were after 1 h: 14.7 ± 6.6 (P < .001), 2 h:
13.7 ± 5.9 (P < .001), 4 h: 12.4 ± 6.8 (P < .001), and 24 h: 5.2 ± 4.6
(P < .001). Differences obtained within the same time point for non-
treated and DBG-treated skin were at 1 h: 12.8 ± 8.7 (P < .001), 2 h:
12.4 ± 6.4 (P < .001), 4 h: 12.6 ± 6.7 (P < .001) and 24 h: 6.0 ± 5.0
(P < .001). There were no significant differences between the
results obtained after 1 and 2 h, nor between the results obtained
after 2 and 4 h. After application of MBG, SCM values were signifi-
cantly increased after 1, 2, and 4 h, when compared to the respec-
tive baseline values and the non-treated control, somewhat similar
to those attained for DBG. For MBG treated skin mean SCM values
increase after 1 h was 10.0 ± 4.9 (P < .001), 2 h: 8.9 ± 5.4 (P < .001)
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and 4 h 7.4 ± 5.8 (P < .001), and compared to non-treated area at
1 h it was 8.2 ± 7.0 (P < .001), 2 h: 7.7 ± 6.6 (P < .001) and 4 h:
7.8 ± 6.8 (P < .001). However, 24 h after the application of MBG
the increase was not statistically significant (SCM values have been
changed compared to baseline and NC for 1.6 ± 4.9 and 2.5 ± 4.7,
respectively).
Since the two investigated products appear to have the same
qualitative composition, it was of interest to investigate whether their
efficacy is also the same. In Figure 1A, it could be observed that SCM
values were more increased after DBG compared to MBG application
at every time point. The fact that the DBG sample induced a signifi-
cant increase after 24 h in skin moisturization levels while the MBG
sample did not, indicates differences in their efficacy.
Study 2 was conducted on chemically induced dry skin and
obtained results are presented in Figure 1B. After application of DBG,
the results attained for dry skin were comparable to those for normal
skin. Skin moisturization was significantly increased after 1, 2, 4, and
24 h, when compared to baseline values (differences after 1 h:
17.8 ± 4.6, 2 h: 15.7 ± 6.3, 4 h: 15.0 ± 5.1, 24 h: 5.7 ± 4.9; P < .001)
and to the non-treated control (differences at 1 h: 14.8 ± 5.8, 2 h:
11.8 ± 6.9, 4 h: 11.4 ± 7.4, 24 h: 4.9 ± 4.1; P < .001).
Following MBG application to the dry skin, findings were again
comparable to the Study 1. Therefore, when applied onto dry skin,
MBG initially increases the moisture content, up to 4 h, but after 24 h
the increase could not be considered statistically significant.
When the results of these different treatments are compared,
DBG moistutization effect was significantly better when compared to
the effect of MBG in every assessed time point. SCM values were sig-
nificantly higher after DBG treatment for 5.0 ± 5.2 (P < .05) after 1 h,
5.2 ± 5.7 (P < .05) after 2 h, 5.5 ± 6.1 (P < .05) after 4 h and after 24 h
for 2.9 ± 3.8 (P < .05).
4 | DISCUSSION
The results indicate that both emollients provide significant
moisturization effects 4 h after the application on normal, as well as
on dry skin. The fact that investigated MBG did not significantly
increase SCM levels of either normal or dry skin 24 h after the appli-
cation, implies the necessity of more frequent MBG application in
order to obtain a satisfactory emollient effect. However, it is generally
accepted that many patients fail to adhere to the recommended fre-
quent emollient application.24
When the effect on normal and dry skin between samples is com-
pared, the DBG moisturization effect was better when compared to
the effect of MBG at every assessed time point after the application.
The relevance of these findings suggests that, regardless of whether
the compared emollient formulations appear to be qualitatively the
same, their inherent microstructure may have a profound effect on
the product performance.
For licensed medicines, regulatory authorities require generic
products to be both pharmaceutically equivalent and bioequivalent to
the innovator in order to substantiate therapeutic equivalence and
interchangeability. To establish bioequivalence, for most topically
applied dermatological products, comparative clinical endpoint trials
are required. For the post approval changes, in order to reassure regu-
lators that changes have not compromised bioequivalence, manufac-
turers have to follow regulatory guidance, which are not restricted to
clinical trials but in vitro methods could be used as well.25 For generic
substance-based Class I medical devices registered in the EU, little or
no attention is given to bioequivalence. The results of the studies
presented here demonstrate that the skin moisturization effects of
MBG are inferior to the innovator product, DBG, in relation to both
the magnitude and duration of the hydration effect. Although Class I
F IGURE 1 A, Stratum corneum moisturization (SCM) mean values (a.u) with 95% confidence intervals obtained in the Study 1 (normal skin)
and B, Stratum corneum moisturization (SCM) mean values (a.u) with 95% confidence intervals obtained in the Study 2 (dry skin); violet line—
DBG treatment, blue line—MBG treatment, and gray line—non-treated control (NC); statistically significant difference compared to *—basal values
(P < .001), #—non-treated control (P < .001) and +—another treatment (P < .05)
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medical devices contain no active ingredients as such, their qualitative
and quantitative compositions as well as their production methods,
equipment, etc. are equally important and more attention should be
given to their investigations.
Taking into account that both emollient preparations appear to
have similar compositions, and the fact that quantitative formulation
and employed manufacturing processes were unknown to the investi-
gators, the observed difference in skin moisturization performance
may be attributed to the difference in the two emulsion systems'
microstructure. This is in line with the three levels of product equiva-
lence commonly controlled by the regulatory agencies: qualitative
(Q1) and quantitative (Q2) composition and the arrangement of mat-
ter and microstructure of topical formulations.3 Namely, according to
the composition declared by both manufacturers, their similarity is
evident at the Q1 level, but the Q2 level equivalence cannot be
assumed.
The quantitative aspect of particular ingredients, alongside the
selection of specific manufacturing parameters, determine the final
microstructure and sensory properties of an emulsion type prod-
uct.26,27 Within the investigated products, stabilized via the combina-
tion of a typical hydrophilic polymer (Carbomer) and a predominantly
lipophilic surfactant (Sorbitan laurate), a unique emulsion system is
formed, offering the possibility for diverse modes of water immobili-
zation and plenty of variations in textural and rheological behavior.
This scope for diversion is further complicated by the absence of data
standardizing the quality of each ingredient. The names of the ingredi-
ents may be identical, but that provides no guarantee of interchange-
ability as regards chemical and physical conformity.
Obtained results are useful and relevant within the scope of our
investigation, but it is important to mention that they may not neces-
sarily apply to people with certain dry skin conditions, and achieved
differences in SCM may not be translated into clinically important for
some skin disorders, since our studies comprised healthy participants.
5 | CONCLUSION
The obtained results are directly applicable in an everyday physician's
practice, since they confirm that a simple choice of apparently the
same ingredients/formulation components is not sufficient for com-
plete interchangeability of formulations. Our study contributes to the
standpoint that decisions on the appropriate emollient treatment
should be founded on evidence-based information on actual product
efficacy, since other critical quality attributes, such as quality of the
material used, the inherent microstructure and the general arrange-
ment of matter within the formulation, may prove to have a decisive
influence on the treatment outcome.
The investigated emollient preparations successfully elevated skin
moisturization in normal and induced dry skin 4 h after single applica-
tion. Yet only the DBG provided statistically significant SCM increase
24 h after the treatment, implying its capability to provide prolonged
skin moisturization. Additionally, comparative analysis of the two
treatments revealed that all SCM values attributed to the DBG
treatment were significantly elevated at each assessed time point, rel-
ative to the MBG treatment.
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